Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy.

The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.